Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2016 | Targeted therapies for CLL: new data and unanswered questions

Jennifer Brown • 3 Jun 2016
ASCO 2016
Chronic Lymphocytic Leukemia Ibrutinib Idelalisib

Jennifer Brown, MD, PhD from the Dana-Farber Cancer Institute, Boston, MA gives an overview of her talk on targeted therapy in chronic lymphocytic leukemia (CLL) held at the American Society of Oncology (ASCO) 2016 Annual Meeting in Chicago, IL. Dr Brown adresses unanswered questions such as how to salvage patients who relapse on the BTK inhibitor ibrutinib and how to optimize the management of toxicities some patients experience. Dr Brown further discusses the issues around the trial of the PI-3 kinase inhibitor idelalisib, in particular infections in the setting of neutropenia.

More from Jennifer Brown

1:18
Investigating acquired mutations in patients with R/R CLL who progressed in the ALPINE study
Jennifer Brown • 11 Dec 2023
1:55
Genomic evolution of patients with CLL who progress on pirtobrutinib in the BRUIN trial
Jennifer Brown • 11 Dec 2023
1:43
Extended follow-up of the ALPINE trial: superior outcomes with zanubrutinib in R/R CLL/SLL
Jennifer Brown • 11 Dec 2023
1:24
Sequencing of BTK inhibitors in CLL
Jennifer Brown • 6 Sep 2023

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals